Natural human genetic variations may cause patients to respond differently to the same medication. Therefore, understanding genetic variation in drug targets can maximize efficacy and reduce side ...

Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S. equity markets ...

Adhesion GPCRs are a large class of surface proteins that recognize chemical and mechanical stimuli in the body. The rapidly expanding body of knowledge on the therapeutic targeting of these receptors ...

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and ...

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, a biotechnology company discovering and advancing novel, oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today ...

"Highlighting Strategic Alliances and Innovation, the Global GPCR Targeting Market Report Explores the Role of GPCRs in Drug Discovery and Therapeutics, Featuring Key Players Like Promega, Thermo ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Structure Therapeutics Inc. stands fifth among them. Structure Therapeutics Inc. (NASDAQ:GPCR) is a ...

G protein-coupled receptors (GPCRs) remain one of the most pharmacologically successful drug targets, with 35% of all commercial drugs and 19% of newly approved drugs targeting this protein ...

Researchers in China developed toGC, a new tool that corrects errors in gene annotations using RNA-seq data. Experimentally validated toGC's accuracy, discovering two novel GPCR genes misannotated as ...